Charles Nemeroff

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    Trials 13:106. 2012
  2. pmc Personalized medicine in psychiatry: problems and promises
    Uzoezi Ozomaro
    University of Miami, Leonard M, Miller School of Medicine, Miami, FL, USA
    BMC Med 11:132. 2013
  3. pmc International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
    Leanne M Williams
    BRAINnet Foundation, 71 Stephenson Street, Suite 400, San Francisco, CA, 94105, USA
    Trials 12:4. 2011
  4. ncbi request reprint The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications
    R Brett Lloyd
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Top Med Chem 11:609-17. 2011

Research Grants

  1. PSYCHOBIOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    Charles Nemeroff; Fiscal Year: 2004
  2. NEUROTENSIN, AN ENDOGENOUS NEUROLEPTIC-LIKE PEPTIDE
    Charles Nemeroff; Fiscal Year: 2004
  3. PSYCHOBIOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    Charles Nemeroff; Fiscal Year: 2000
  4. PSYCHOBIOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    Charles Nemeroff; Fiscal Year: 1993
  5. NEUROTENSIN--AN ENDOGENOUS NEUROLEPTIC LIKE PEPTIDE
    Charles Nemeroff; Fiscal Year: 1999
  6. Neurotensin an endogenous neuroleptic-like peptide
    Charles Nemeroff; Fiscal Year: 2007

Collaborators

  • Uzoezi Ozomaro
  • Boadie W Dunlop
  • R Brett Lloyd
  • Leanne M Williams
  • Claes Wahlestedt
  • Helen S Mayberg
  • Mark M Goodman
  • D Jeffrey Newport
  • Thaddeus W W Pace
  • Mary E Kelley
  • Vivianne Aponte Rivera
  • Michael J Owens
  • Becky Kinkead
  • Drew Westen
  • Joseph F Cubells
  • Michael Kutner
  • James C Ritchie
  • Elisabeth B Binder
  • W Edward Craighead
  • Stephen R Wisniewski
  • Stephen H Koslow
  • Nicholas J Cooper
  • Alan F Schatzberg
  • Evian Gordon
  • A John Rush

Detail Information

Publications5

  1. pmc Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    Trials 13:106. 2012
    ..Consequently, we initiated a randomized clinical trial designed to identify factors that moderate response to three treatments for MDD among patients never treated previously for the condition...
  2. pmc Personalized medicine in psychiatry: problems and promises
    Uzoezi Ozomaro
    University of Miami, Leonard M, Miller School of Medicine, Miami, FL, USA
    BMC Med 11:132. 2013
    ..In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging...
  3. pmc International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
    Leanne M Williams
    BRAINnet Foundation, 71 Stephenson Street, Suite 400, San Francisco, CA, 94105, USA
    Trials 12:4. 2011
    ..The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators...
  4. ncbi request reprint The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications
    R Brett Lloyd
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Top Med Chem 11:609-17. 2011
    ..Perhaps the best studied central nervous system (CNS) component of this system is corticotropin-releasing factor (CRF), and considerable research has focused on its role in the HPA axis, as well in extrahypothalamic brain regions...

Research Grants25

  1. PSYCHOBIOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    Charles Nemeroff; Fiscal Year: 2004
    ..These studies will provide novel information on the role of CRF nepronal systems in the pathophysiology of depression, in animal models of systemic CRF1 receptor antagonist administration. ..
  2. NEUROTENSIN, AN ENDOGENOUS NEUROLEPTIC-LIKE PEPTIDE
    Charles Nemeroff; Fiscal Year: 2004
    ....
  3. PSYCHOBIOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    Charles Nemeroff; Fiscal Year: 2000
    ..These studies will furnish novel information on the role of CRF-containing neural systems in both the stress and response and in the pathophysiology of depression. ..
  4. PSYCHOBIOLOGY OF CORTICOTROPIN-RELEASING FACTOR
    Charles Nemeroff; Fiscal Year: 1993
    ..Such studies have important implications for the development of novel treatments for major depression and perhaps anxiety disorders...
  5. NEUROTENSIN--AN ENDOGENOUS NEUROLEPTIC LIKE PEPTIDE
    Charles Nemeroff; Fiscal Year: 1999
    ..These studies will provide novel information concerning the role of NT systems in the mechanism of action of antipsychotic drugs, and in the pathophysiology of schizophrenia. ..
  6. Neurotensin an endogenous neuroleptic-like peptide
    Charles Nemeroff; Fiscal Year: 2007
    ..Drugs that act upon NT circuits represent just such a novel research direction. ..